1235449-52-1

Basic information

• Product Name: PI3Kα inhibitor 1
• Synonyms: CUDC-908
• CAS NO: 1235449-52-1
• Molecular Formula: C23H25N9O3S
• Molecular Weight: 507.5681
• Mol File: 1235449-52-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PI3Kα inhibitor 1(CAS DataBase Reference)
• NIST Chemistry Reference: PI3Kα inhibitor 1(1235449-52-1)
• EPA Substance Registry System: PI3Kα inhibitor 1(1235449-52-1)

Safety Data

• Hazardous Substances Data: 1235449-52-1(Hazardous Substances Data)

Usage

General Description

PI3Kα inhibitor 1 is a chemical compound that functions as an inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) enzyme. This enzyme plays a crucial role in cell growth, proliferation, and survival, and is often overactive in many types of cancer. By targeting PI3Kα, this inhibitor has the potential to halt the uncontrolled cell division and growth seen in cancer. Additionally, it may also have applications in combating other diseases such as diabetes, cardiovascular diseases, and immune disorders in which PI3Kα is involved. The chemical structure of PI3Kα inhibitor 1 allows it to selectively bind to and inhibit the activity of PI3Kα, making it a promising candidate for drug development and research in the field of oncology and other related disease areas.

Upstream product

• 227939-01-7 5-bromo-2-(N-methyl-N-(t-butoxycarbonyl)amino)pyridine 
• 84539-30-0 5-bromo-N-methylpyridin-2-amine 
• 624-28-2 2,5-dibromopyridine 
• 1235450-25-5 2-[(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-amino]-pyrimidine-5-carboxylic acid ethyl ester 
• 955979-15-4 1-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)-N-methylmethanamine 
• 885618-31-5 2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde 
• 16234-15-4 2-chloro-4-morpholinothieno[3,2-d]pyrimidine 
• 16234-14-3 2,4-dichlorothieno[3,2-d]pyrimidine 
• 16233-51-5 1H-thieno[3,2-d]pyrimidine-2,4-dione 

Relevant articles and documents

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.